Randomized phase II study of valproic acid in combination with bevacizumab and oxaliplatin/fluoropyrimidine regimens in patients with RAS-mutated metastatic colorectal cancer: the REVOLUTION study protocol

BACKGROUND: Despite effective treatments, metastatic colorectal cancer (mCRC) prognosis is still poor, mostly in RAS-mutated tumors, thus suggesting the need for novel combinatorial therapies. Epigenetic alterations play an important role in initiation and progression of cancers, including CRC. Hist...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Ther Adv Med Oncol
Main Authors: Avallone, Antonio, Piccirillo, Maria Carmela, Di Gennaro, Elena, Romano, Carmela, Calabrese, Filomena, Roca, Maria Serena, Tatangelo, Fabiana, Granata, Vincenza, Cassata, Antonio, Cavalcanti, Ernesta, Maurea, Nicola, Maiolino, Piera, Silvestro, Lucrezia, De Stefano, Alfonso, Giuliani, Francesco, Rosati, Gerardo, Tamburini, Emiliano, Aprea, Pasquale, Vicario, Valeria, Nappi, Anna, Vitagliano, Carlo, Casaretti, Rossana, Leone, Alessandra, Petrillo, Antonella, Botti, Gerardo, Delrio, Paolo, Izzo, Francesco, Perrone, Francesco, Budillon, Alfredo
Formato: Artigo
Idioma:Inglês
Publicado em: SAGE Publications 2020
Assuntos:
Study Protocol
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7425244/
https://ncbi.nlm.nih.gov/pubmed/32849914
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/1758835920929589
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados